Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Mirikizumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 01 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top